MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, EKSO had $2,824K increase in cash & cash equivalents over the period. -$2,123K in free cash flow.

Cash Flow Overview

Change in Cash
$2,824K
Free Cash flow
-$2,123K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of series...
    • Accounts receivable
    • Loss (gain) on revaluation of wa...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Principal payments under notes p...
    • Deferred revenues
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Changes in provision for credit losses on accounts receivable
--42 -13 5
Net loss
-6,885 -4,674 -1,421 -5,600
Depreciation and amortization
454 451 367 755
Loss on impairment of intangible asset
0 570 0 180
Changes in provision for credit losses on accounts receivable
323 ---
Loss (gain) on revaluation of warrant liabilities
-727 0 0 1
Finance cost associated with warrant issuance
145 ---
Loss on impairment of right-of-use asset
89 ---
Stock-based compensation expense
114 783 234 457
Loss on modification of warrant
-0 0 0
Common stock contribution to 401 plan
0 72 64 15
Unrealized loss (gain) on foreign currency transactions
-239 -4 4 1,965
Accounts receivable
-2,423 1,099 1,507 -3,052
Inventories
-168 -112 -494 881
Prepaid expenses and other assets, current and noncurrent
115 -260 283 164
Accounts payable
679 -232 216 -121
Accrued, lease and other liabilities, current and noncurrent
-188 -348 -38 -716
Deferred revenues
-296 -188 -170 -425
Net cash used in operating activities
-2,123 -4,331 -2,061 -5,409
Acquisition of property and equipment
0 126 12 50
Net cash used in investing activities
0 -126 -12 -50
Principal payments under notes payable
313 312 313 625
Retirement of term loan-Term Loan
-0 2,000 -
Proceeds from issuance of common stock, net
-3,232 -48 914
Proceeds from issuance of series b convertible preferred stock and january 2026 private placement warrants, net
5,265 ---
Proceeds from exercise of warrants, net
0 0 0 3,856
Proceeds from issuance of convertible promissory note, net-Promissory Note
-1 1,924 -
Net cash provided by financing activities
4,952 2,921 -437 4,145
Effect of exchange rate changes on cash
-5 -17 -10 63
Net increase in cash
2,824 -1,553 -2,520 -1,251
Cash and restricted cash at beginning of period
1,169 2,722 6,493 -
Cash and restricted cash at end of period
3,993 1,169 2,722 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofseries b convertible...$5,265K Net cash provided byfinancing activities$4,952K Canceled cashflow$313K Net increase in cash$2,824K Canceled cashflow$2,128K Principal payments undernotes payable$313K Accounts receivable-$2,423K Loss (gain) onrevaluation of warrant...-$727K Accounts payable$679K Depreciation andamortization$454K Changes in provision forcredit losses on...$323K Unrealized loss (gain) onforeign currency...-$239K Inventories-$168K Finance cost associatedwith warrant...$145K Stock-based compensationexpense$114K Loss on impairment ofright-of-use asset$89K Net cash used inoperating activities-$2,123K Effect of exchange ratechanges on cash-$5K Canceled cashflow$5,361K Net loss-$6,885K Deferred revenues-$296K Accrued, lease and otherliabilities, current and...-$188K Prepaid expenses andother assets, current...$115K

EKSO BIONICS HOLDINGS, INC. (EKSO)

EKSO BIONICS HOLDINGS, INC. (EKSO)